Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.43 USD 2.65% Market Closed
Market Cap: 849.5m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
PP&E Net
$40.4m
CAGR 3-Years
-16%
CAGR 5-Years
-6%
CAGR 10-Years
7%
Pharming Group NV
AEX:PHARM
PP&E Net
$30.7m
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
18%
ProQR Therapeutics NV
NASDAQ:PRQR
PP&E Net
€14.4m
CAGR 3-Years
-6%
CAGR 5-Years
43%
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
PP&E Net
$36.9m
CAGR 3-Years
48%
CAGR 5-Years
44%
CAGR 10-Years
81%
Merus NV
NASDAQ:MRUS
PP&E Net
$22.5m
CAGR 3-Years
44%
CAGR 5-Years
17%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
PP&E Net
$2.5m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
849.5m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's PP&E Net?
PP&E Net
40.4m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's PP&E Net amounts to 40.4m USD.

What is Uniqure NV's PP&E Net growth rate?
PP&E Net CAGR 10Y
7%

Over the last year, the PP&E Net growth was -47%. The average annual PP&E Net growth rates for Uniqure NV have been -16% over the past three years , -6% over the past five years , and 7% over the past ten years .

Back to Top